Arch Biopartners Inc.

61 articles with Arch Biopartners Inc.

• Arch Biopartners Expands Dosing in Phase I Trial for Metablok to Increase Dose Range for Future Phase II Studies

  3/4/2020

  Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that it is expanding the dose range of Metablok (LSALT peptide) for future Phase II trials targeting inflammation in the lung, the kidney and/or the liver by adding a cohort of eight healthy volunteers to receive the highest daily dose tested to date for three consecutive days

• Arch Biopartners Closes Convertible Note Financing - Feb. 06, 2020

  2/6/2020

  Arch Biopartners Inc.,, announced it has closed the non-brokered, unsecured convertible note financing it disclosed in a press release on February 4th for net proceeds of CAD $500,000.

• Arch Biopartners Arranges Convertible Note Financing

  2/4/2020

  TORONTO, Feb. 04, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced it has arranged a non-brokered, unsecured convertible note (“Note”) financing for gross proceeds of CAD $500,000 (the “Offering”).

• Arch Biopartners Announces Metablok Achieves Primary Endpoints of Safety and Tolerability in Phase I Trial

  12/18/2019

  Metablok is the Company’s lead drug candidate for treating organ damage caused by inflammation

• Arch Biopartners Announces Issuance of U.S. Patent for Dipeptidase-1 Inhibitor Drug for Use in Acute Kidney Injury

  12/4/2019

  This is the first patent issued protecting the method of use for the dipeptidase-1 (DPEP-1) inhibitor, cilastatin, for ischemia reperfusion injury, where DPEP-1 mediated inflammation plays a major role.

• Arch Provides Interim Update on Phase I Trial for Metablok (LSALT Peptide)

  11/7/2019

  Arch Biopartners Inc., announced that the Phase I human trial of Metablok, the Company’s lead drug candidate for treating organ damage caused by inflammation, has met the primary endpoints of safety and tolerability in the trial’s three single ascending dose cohorts of healthy volunteers.

• Arch Biopartners Closes Convertible Note Financing

  2/16/2018

  The Note matures on February 28, 2021 and will be convertible, at the option of the holder, into common shares in the capital of the Company at a price per Common Share of $0.60.

• Arch Biopartners Announces AB569 Phase I Human Trial Begins Patient Recruitment and Enrollment Stage

  2/13/2018

  AB569 is the Company’s inhalation drug candidate for treating antibiotic-resistant bacterial infections in the lungs of CF and COPD patients.

• Arch Biopartners Announces Completion of GMP Manufacturing of AB569 and Start Date of Phase I Trial

  12/6/2017

  AB569 is the Company’s inhalation drug candidate for treating antibiotic-resistant bacterial infections in the lungs of cystic fibrosis.

• Arch Biopartners Closes Convertible Note Financing

  10/25/2017

  Arch Biopartners Inc. announced it has closed a non-brokered, unsecured convertible note financing for gross proceeds of CAD $500,000 on October 23, 2017.

• Arch Biopartners Inc.' GMP Manufacturing Of AB569 Progresses To Final Production Stage

  10/2/2017

• Arch Biopartners Inc. Retains Market Maker And Arranges Non Brokered Private Placement Financing

  7/25/2017

• Dalton Pharma Services Announces A Drug Development And GMP Manufacturing Services Agreement With Arch Biopartners Inc.

  5/9/2017

• Arch Biopartners Inc. Submits Orphan Drug Application For AB569 To European Medicines Agency

  2/3/2016

• Arch Biopartners Inc. Obtains Exclusive License for CU Patent

  12/7/2010

• Arch Biopartners Inc. Announces Change in Year End

  11/19/2010

• Arch Biopartners Inc. to Present at the Small Cap Conference in Calgary Oct 6; Vancouver Oct 28, 2010

  10/5/2010

• Arch Biopartners Inc. Acquires Option to License Anti Cancer Compounds From University of Colorado

  9/21/2010

• Arch Biopartners Inc. Scientists Identify Key Pathways and Therapeutic Targets in Kidney Disease and C. difficile Colitis

  8/10/2010

• Arch Biopartners Inc. Launches Website

  7/14/2010